ÂÜÀòÂÒÂ×

Chris Erdman, MPH, is Senior Vice President of Investor Relations and Corporate Communications at Morphic Therapeutic where he is responsible for investor engagement and corporate affairs. Prior to Morphic, Chris was Vice President of Investor Relations and Corporate Communications at CRISPR Therapeutics, a pioneering gene editing company. Chris has more than two decades of strategic communications experience in biotechnology, both in public companies and as the leader of a life sciences advisory firm.

Chris holds a Master of Public Health degree from the Boston University School of Public Health and a BA from Hobart College.